Advertisement

Advertisement

ANIP Stock Latest News

ANI Pharmaceuticals initiated with a Hold at Canaccord

The FlyANI Pharmaceuticals initiated with a Hold at Canaccord

ANI Pharmaceuticals intends to appeal rulings in CG Oncology matter

PremiumThe Fly

ANI Pharmaceuticals intends to appeal rulings in CG Oncology matter

5d ago

ANI Pharmaceuticals initiated with a Hold at Canaccord

PremiumThe Fly

ANI Pharmaceuticals initiated with a Hold at Canaccord

5d ago

Buy Rating Reaffirmed on Cortrophin Strength and ILUVIEN Upside; $121 Price Target Maintained

PremiumRatings

Buy Rating Reaffirmed on Cortrophin Strength and ILUVIEN Upside; $121 Price Target Maintained

9d ago

ANI Pharmaceuticals reports ‘positive’ results from Phase 4 Synchronicity trial

PremiumThe Fly

ANI Pharmaceuticals reports ‘positive’ results from Phase 4 Synchronicity trial

9d ago

ANI Pharmaceuticals Signals Confident 2026 Growth Path

PremiumCompany AnnouncementsANI Pharmaceuticals Signals Confident 2026 Growth Path

2M ago

ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan

Company Announcements

ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan

2M ago

ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics

Company Announcements

ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics

2M ago

Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum

PremiumRatings

Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum

2M ago

ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30

PremiumThe Fly

ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30

2M ago

ANI raises FY26 adjusted EPS view to $9.19-$9.69 from $8.83-$9.34

PremiumThe Fly

ANI raises FY26 adjusted EPS view to $9.19-$9.69 from $8.83-$9.34

2M ago

ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

3M ago

ANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets

PremiumThe FlyANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets

3M ago

ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP

The Fly

ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP

3M ago

ANI Pharmaceuticals announces publication of iluvien clinical trial results

The Fly

ANI Pharmaceuticals announces publication of iluvien clinical trial results

4M ago

ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors

PremiumCompany Announcements

ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors

5M ago

ANI Pharmaceuticals Signals Strong Growth in 2025 Call

PremiumCompany Announcements

ANI Pharmaceuticals Signals Strong Growth in 2025 Call

5M ago

ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth

PremiumCompany Announcements

ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth

5M ago

ANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98

PremiumThe Fly

ANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98

5M ago

ANI Pharmaceuticals sees FY26 adjusted EPS $8.83-$9.34, consensus $8.64

PremiumThe FlyANI Pharmaceuticals sees FY26 adjusted EPS $8.83-$9.34, consensus $8.64

5M ago

ANIP Upcoming Earnings Report: What to Expect?

Pre-Earnings

ANIP Upcoming Earnings Report: What to Expect?

5M ago

ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim

The Fly

ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >